| · Æóðíàëû
· Êíèãè
· Î ïðîåêòå
·Ýëåêòðîííûå âåðñèè êíèã èçäàòåëüñòâà “Àòìîñôåðà” ïîñòóïèëè â ïðîäàæó
Èçäàòåëüñòâî “Àòìîñôåðà” èäåò â íîãó ñî âðåìåíåì è îòêðûâàåò íà ñâîåì ñàéòå ðàçäåë ýëåêòðîííûõ âåðñèé ñâîèõ êíèã. Òåïåðü âû ìîæåòå ïðèîáðåñòè íå òîëüêî òðàäèöèîííóþ áóìàæíóþ êíèãó â êàðòîííîì ïåðåïëåòå, íî è .pdf-ôàéë, ñíàáæåííûé ãèïåðññûëêàìè íà êàæäóþ ãëàâó èçäàíèÿ.  ýëåêòðîííîé âåðñèè ïðîùå îòûñêàòü ðèñóíîê è òàáëèöó. ×òîáû îáðàòèòüñÿ ê íèì, äîñòàòî÷íî íàæàòü íà ññûëêó íà êàæäûé èç íèõ. Èñ÷åçëà çàâèñèìîñòü îò òèðàæà – âû ìîæåòå ïðèîáðåñòè äàæå òå áåñòñåëëåðû, òèðàæ êîòîðûõ óæå ðàçîøåëñÿ, òàêèå êàê “Ñàðêîèäîç” èëè “Çàáîëåâàíèÿ îðãàíîâ äûõàíèÿ ïðè áåðåìåííîñòè”. Óïðîñòèëîñü ïîëó÷åíèå âàìè êíèã – â òå÷åíèå äâóõ ðàáî÷èõ äíåé ïîñëå îïëàòû òðåáóåìûå ôàéëû ïðèäóò íà âàø e-mail. Íó è íàêîíåö, öåíà – ýëåêòðîííûå âåðñèè íàøèõ êíèã ãîðàçäî äåøåâëå, ÷åì áóìàæíûå èçäàíèÿ.
Çàêàçûâàéòå ýëåêòðîííûå âåðñèè êíèã èçäàòåëüñòâà “Àòìîñôåðà” íà ñàéòå, à òàêæå ïî òåëåôîíó: (495) 730-63-51 è ïî e-mail: atm-press2012@yandex.ru
ÈÍÒÅÐÍÅÒ-ÌÀÃÀÇÈÍ
|
|
 | |
Ëå÷åáíîå äåëî
2012 / N 1
Äâîéíûå äîçû èíãèáèòîðîâ ïðîòîííîé ïîìïû – ïóòü ïîâûøåíèÿ ýôôåêòèâíîñòè òðîéíîé àíòèõåëèêîáàêòåðíîé òåðàïèè ïåðâîé ëèíèè (ñïèñîê ëèòåðàòóðû)
Þ.À. Êó÷åðÿâûé, Å.Â. Áàðêàëîâà
Ñïèñîê ëèòåðàòóðû
1. Basso D., Plebani M., Kusters J.G. Pathogenesis of Helicobacter pylori infection // Helicobacter. – 2010. – Vol.15 (Suppl. 1). – P.14-20.
2. O'ConnorA., GisbertJ.P., McNamaraD., O'MorainC. TreatmentofHelicobacterpyloriinfection 2010 // Helicobacter. – 2010. – Vol.15(Suppl. 1). – P.46-52.
3. Nakajima S., Nishiyama Y., Yamaoka M., Yasuoka T., Cho E. Changes in the prevalence of Helicobacter pylori infection and gastrointestinal diseases in the past 17 years // J. Gastroenterol. Hepatol. – 2010. – Vol.25 (Suppl. 1). - S99-S110.
4. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/GGuidance/UCM184500.pdf
5. Buzás G.M. First-line eradication of Helicobacter pylori: are the standard triple therapies obsolete? A different perspective // World J. Gastroenterol. – 2010. – Vol.16(31). – P.3865-3870.
6. Graham D.Y., Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance // Gut. – 2010. – Vol.59(8). – P.1143-1153.
7. Malfertheiner P., Megraud F., O'Morain C., Bazzoli F., El-Omar E., Graham D. et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report // Gut. – 2007. – Vol.56(6). – P.772-781.
8. Fuccio L., Minardi M.E., Zagari R.M., Grilli D., Magrini N., Bazzoli F. Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication // Ann. Intern. Med. – 2007. – Vol.147(8). – P.553-562.
9. Chey W.D., Wong B.C. American College of Gastroenterology guideline on the management of Helicobacter pylori infection // Am. J. Gastroenterol. – 2007. – Vol.102. – P.1808-1825.
10. Malfertheiner P., Selgrad M. Helicobacter pylori infection and current clinical areas of contention // Curr. Opin. Gastroenterol. – 2010. – Vol.26(6). – P.618-623.
11. Fischbach L.A., Goodman K.J., Feldman M. et al. Sources of variation of Helicobacter pylori treatment success in adults worldwide: a meta-analysis // Int. J. Epidemiol. – 2002. – Vol.31. – P.128-139.
12. Calabresi L., Pazzucconi F., Ferrara S., Di Paolo A., Tacca M.D., Sirtori C. Pharmacokinetic interactions between omeprazole / pantoprazole and clarithromycin in health volunteers // Pharmacol. Res. – 2004. – Vol.49(5). – P.493-499.
13. Scott D., Weeks D., Melchers K. et al. The life and death of Helicobacter pylori // Gut. – 1998. – Vol.43 (Suppl. 1). - S56-S60.
14. Erah P.O., Goddard A.F., Barrett D.A., Shaw P.N., Spiller R.C. The stability of amoxycillin, clarithromycin and metronidazole in gastric juice: relevance to the treatment of Helicobacter pylori infection // J. Antimicrob. Chemother. – 1997. – Vol.39(1). – P.5-12.
15. Vallve M., Vergara M., Gisbert J.P., Calvet X. Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta-analysis // Aliment. Pharmacol. Ther. – 2002. – Vol.16(6). – P.1149-1156.
16. Anagnostopoulos G.K., Tsiakos S., Margantinis G., Kostopoulos P., Arvanitidis D. Esomeprazole versus omeprazole for the eradication of Helicobacter pylori infection: results of a randomized controlled study // J. Clin. Gastroenterol. – 2004. - 38(6). – P.503-506.
17. Choi H.S., Park D.I., Hwang S.J. et al. Double-dose, new-generation proton pump inhibitors do not improve Helicobacter pylori eradication rate // Helicobacter – 2007. – Vol.12. – P.638-642.
18. Gisbert J.P., Dominguez-Munoz A., Dominguez-Martin A., Gisbert J.L., Marcos S. Esomeprazole-based therapy in Helicobacter pylori eradication: any effect by increasing the dose of esomeprazole or prolonging the treatment? // Am. J. Gastroenterol. – 2005. – Vol.100. – P.1935-1940.
19. Hsu P.I., Lai K.H., Wu C.J. et al. High-dose versus low-dose esomeprazole-based triple therapy for Helicobacter pylori infection // Eur. J. Clin. Invest. – 2007. – Vol.37. – P.724-730.
20. Manes G., Pieramico O., Perri F., Vaira D., Giardullo N., Romano M. et al. Twice daily standard dose of omeprazole achieves the necessary level of acid inhibition for Helicobacter pylori eradication. A randomized controlled trial using standard and double doses of omeprazole in triple therapy // Dig. Dis. Sci. – 2005. – Vol.50. – P.443-448.
21. Sheu B.S., Kao A.W., Cheng H.C., Hunag S.F., Chen T.W., Lu C.C., Wu J.J. Esomeprazole 40 mg twice daily in triple therapy and the efficacy of Helicobacter pylori eradication related to CYP2C19 metabolism // Aliment. Pharmacol. Ther. - 2005. – Vol.21(3). – P.283-288.
22. Villoria A., Garcia P., Calvet X., Gisbert J.P., Vergara M. Meta-analysis: high-dose proton pump inhibitors vs. standard dose in triple therapy for Helicobacter pylori eradication // Aliment. Pharmacol. Ther. – 2008. – Vol.28(7). – P.868-877.
23. Graham D.Y., Shiotani A. New concepts of resistance in the treatment of Helicobacter pylori infections // Nat. Clin. Pract. Gastroenterol. Hepatol. – 2008. – Vol.5(6). – P.321-331.
24. Sugimoto M., Furuta T., Shirai N., Kodaira C., Nishino M., Ikuma M. et al. Evidence that the degree and duration of acid suppression are related to Helicobacter pylori eradication by triple therapy // Helicobacter. – 2007. – Vol.12(4). –
|
[ Ñîäåðæàíèå âûïóñêà N 1 | Âûïóñêè æóðíàëà | Ñïèñîê æóðíàëîâ ] |
|
|
